<DOC>
	<DOCNO>NCT00680485</DOCNO>
	<brief_summary>This study evaluate safety , tolerability exposure repeat escalate oral dos , load dose/maintenance dose regimen GSK580416 co administer ketoconazole , PGP/CYP3A4 inhibitor .</brief_summary>
	<brief_title>Evaluation Safety , Tolerability Pharmacokinetics Repeat Oral Doses GSK580416</brief_title>
	<detailed_description>A three part study healthy adult subject evaluate safety , tolerability pharmacokinetics repeat escalate oral dos GSK580416 ; safety , tolerability , pharmacokinetics GSK580416 follow load dose regimen ; effect ketoconazole pharmacokinetics GSK580416</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<criteria>Healthy adult ( determined medical evaluation include history , physical exam , vital sign , laboratory test , cardiac monitoring ) Aged 1860yrs , BMI 1931kg/m2 . Females must nonchildbearing potential . QTc &lt; 450 msec screening . Subjects must able give consent comply restriction study . Clinically significant CNS , cardiac , pulmonary , metabolic , renal , hepatic GI condition history may place subject unacceptable risk may interfere absorption , distribution , metabolism , excretion drug . Positive urine drug screen . Positive urine test alcohol . Positive HIV Hep B and/or C assay . History regular tobacco use within 3 monts prior screen cotinine level indicative smoking screening . History regular alcohol consumption ( 14 units/week woman 21 units/week men ) . History drug abuse dependence within 12 month study . Participation another drug trial within 30 day first dose . Exposure 4 new chemical entity within 12 month first dose . Use prescription nonprescription drug include vitamin , dietary supplement , herbal within 7 day first dose St. John 's Wort within 28 day first dose . Consumption red wine , Seville oranges , grapefruit , grapefruit juice within 14 day first dose . Donation blood excess 500 mL within 56 day dose . No blood donation allow 30 day prior study participation . A positive immunochemical fecal occult blood test screening . History sensitivity study medication . History sensitivity heparin heparininduced thrombocytopenia . History orthostatic hypotension orthostatic hypotension screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>GSK580416</keyword>
	<keyword>ketoconazole interaction</keyword>
	<keyword>pleuromutilin</keyword>
	<keyword>oral dose</keyword>
</DOC>